Form 4: Pacira BioSciences Director Receives Stock Option Grant

Director Thomas G. Wiggans was granted 32,675 stock options in Pacira BioSciences, Inc. as part of standard compensation.

Summary

• Director Thomas G. Wiggans received a grant of 32,675 stock options on June 10, 2026.
• The options have an exercise price of $23.42 per share.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the granted options.
• Dependence on the director's continuous service for full vesting of the equity grant.

Future Outlook

The options vest over a three-year period, with one-third vesting on the first anniversary and the remainder in equal monthly installments thereafter, contingent on continued service.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure long-term commitment and alignment with corporate performance goals.

Comparison to Industry Standards

• The grant structure follows standard industry vesting schedules for non-employee directors.
• The exercise price is consistent with standard market-based pricing for equity incentive plans.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of one-third of the options on June 10, 2027.
• Continued monthly vesting of remaining options through June 2029.

Key Dates

Keywords

Pacira BioSciences, PCRX, Form 4, Insider Trading, Stock Options, Director Compensation